Discovery of drugs that possess activity against feline leukemia virus

Journal of General Virology

Volumn 93, Issue 4, 2012, Pages 900-905

  Greggs III, Willie M ^a,b   Clouser, Christine L ^a   Patterson, Steven E ^a,c   Mansky, Louis M ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GEMCITABINE; RALTEGRAVIR; TENOFOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; FELINE LEUKEMIA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; AZACITIDINE; CAT DISEASES; CATS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; LEUKEMIA VIRUS, FELINE; LEUKEMIA, FELINE; ORGANOPHOSPHONATES; PYRROLIDINONES; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS;

FELINE LEUKEMIA VIRUS; GAMMARETROVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84858182899     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.039909-0     Document Type: Article

References (28)

1. Bebenek, K., Roberts, J. D. & Kunkel, T. A. (1992). The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J Biol Chem 267, 3589-3596.
2. Beck-Engeser, G. B., Eilat, D., Harrer, T., J Jäck, H. M. & Wabl, M. (2009). Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc Natl Acad Sci U S A 106, 20865-20870.
3. Boyer, P. L., Gao, H. Q., Clark, P. K., Sarafianos, S. G., Arnold, E. & Hughes, S. H. (2001). YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro. J Virol 75, 6321-6328.
4. Buzón, M. J., Massanella, M., Llibre, J. M., Esteve, A., Dahl, V., Puertas, M. C., Gatell, J. M., Domingo, P., Paredes, R. & other authors (2010). HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16, 460-465.
5. Cattori, V., Tandon, R., Riond, B., Pepin, A. C., Lutz, H. & Hofmann-Lehmann, R. (2009). The kinetics of feline leukaemia virus shedding in experimentally infected cats are associated with infection outcome. Vet Microbiol 133, 292-296.
6. Cattori, V., Weibel, B. & Lutz, H. (2011). Inhibition of feline leukemia virus replication by the integrase inhibitor raltegravir. Vet Microbiol 152, 165-168.
7. Cerqueira, N. M., Fernandes, P. A. & Ramos, M. J. (2007). Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 13, 8507-8515.
8. Clouser, C. L., Patterson, S. E. & Mansky, L. M. (2010). Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol 84, 9301-9309.
9. Clouser, C. L., Holtz, C. M., Mullett, M., Crankshaw, D. L., Briggs, J. E., Chauhan, J., VanHoutan, I. M., Patterson, S. E. & Mansky, L. M. (2011). Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS One 6, e15840.
10. Essex, M., Klein, G., Snyder, S. P. & Harrold, J. B. (1971). Correlation between humoral antibody and regression of tumours induced by feline sarcoma virus. Nature 233, 195-196.
11. Garcia, J. S., Jain, N. & Godley, L. A. (2010). An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther 3, 1-13.
12. Gingerich, D. A. (2008). Lymphocyte T-cell immunomodulator (LTCI): review of the immunopharmacology of a new veterinary biologic. Intern J Appl Res Vet Med 6, 61-68.
13. Hartmann, K., Block, A., Ferk, G., Vollmar, A., Goldberg, M. & Lutz, H. (1998). Treatment of feline leukemia virus-infected cats with paramunity inducer. Vet Immunol Immunopathol 65, 267-275.
14. Haschek, W.M., Weigel, R.M., Scherba, G., DeVera, M. C., Feinmehl, R., Solter, P., Tompkins, M. B. & Tompkins, W. A. (1990). Zidovudine toxicity to cats infected with feline leukemia virus. Fundam Appl Toxicol 14, 764-775.
15. Jamburuthugoda, V. K., Santos-Velazquez, J. M., Skasko, M., Operario, D. J., Purohit, V., Chugh, P., Szymanski, E. A., Wedekind, J. E., Bambara, R. A. & Kim, B. (2008). Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J Biol Chem 283, 9206-9216.
16. Kearney, B. P., Flaherty, J. F. & Shah, J. (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43, 595-612.
17. Malet, I., Delelis, O., Valantin, M. A., Montes, B., Soulie, C., Wirden, M., Tchertanov, L., Peytavin, G., Reynes, J. & other authors (2008). Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52, 1351-1358.
18. Operario, D. J., Reynolds, H. M. & Kim, B. (2005). Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases. Virology 335, 106-121.
19. Paprotka, T., Venkatachari, N. J., Chaipan, C., Burdick, R., Delviks-Frankenberry, K. A., Hu, W. S. & Pathak, V. K. (2010). Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol 84, 5719-5729.
20. Poch, O., Sauvaget, I., Delarue, M. & Tordo, N. (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8, 3867-3874.
21. Reigadas, S., Andréola, M. L., Wittkop, L., Cosnefroy, O., Anies, G., Recordon-Pinson, P., Thiébaut, R., Masquelier, B. & Fleury, H. (2010). Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 65, 434-437.
22. Rickard, C. G., Post, J. E., Noronha, F. & Barr, L. M. (1969). A transmissible virus-induced lymphocytic leukemia of the cat. J Natl Cancer Inst 42, 987-1014.
23. Robbins, B. L., Srinivas, R. V., Kim, C., Bischofberger, N. & Fridland, A. (1998). Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis (isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42, 612-617.
24. Rogerson, P., Jarrett, W. & Mackey, L. (1975). Epidemiological studies on feline leukaemia virus infection. I. A serological survey in urban cats. Int J Cancer 15, 781-785.
25. Singh, I. R., Gorzynski, J. E., Drobysheva, D., Bassit, L. & Schinazi, R. F. (2010). Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 5, e9948.
26. Smith, R. A., Gottlieb, G. S. & Miller, A. D. (2010). Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 7, 70.
27. Tavares, L., Roneker, C., Johnston, K., Lehrman, S. N. & de Noronha, F. (1987). 39-Azido-39-deoxythymidine in feline leukemia virus-infected cats: amodel for therapy and prophylaxis of AIDS. Cancer Res 47, 3190-3194.
28. Wang, J., Lohman, G. J. & Stubbe, J. (2009). Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 59-diphosphate. Biochemistry 48, 11612-11621.